Paclitaxel cationic liposomal - CSPC Pharmaceutical Group
Alternative Names: Paclitaxel cationic liposome for injection - CSPC Pharmaceutical GroupLatest Information Update: 29 Apr 2022
At a glance
- Originator CSPC Pharmaceutical Group
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Breast cancer; Pancreatic cancer
Most Recent Events
- 28 Apr 2022 Phase-I clinical trials in Breast cancer in China (Parenteral) before April 2022 (CSPC Pharmaceutical Group pipeline, April 2022)
- 28 Apr 2022 Phase-I clinical trials in Pancreatic cancer in China (Parenteral) before April 2022 (CSPC Pharmaceutical Group pipeline, April 2022)
- 25 Apr 2019 Preclinical trials in Breast cancer in China (Parenteral) before April 2019